Drug Topics
MAY 23, 2024
Recent research on food allergy highlights the mental health concerns of people living with a food allergy, how nutritional intervention can help children with food allergy, and that peanut introduction can reduce rates of new allergy in high-risk infants.
Pharmacy Times
MAY 23, 2024
Data have shown the potential for the therapy to treat several new conditions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
MAY 23, 2024
In an abstract presented at Digestive Disease Week 2024, researchers analyzed the prevalence of obesity in patients with and without celiac disease.
Pharmacy Times
MAY 23, 2024
The GLP-1 market is expected to exceed $100 billion by 2023, according to J.P. Morgan Research, with total users in the United States projected to reach 30 million.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
MAY 23, 2024
Savannah Roberts Clary, PharmD, BCPS, CPGx, a clinical pharmacist with Aegis Sciences Corporation, discusses what tianeptine is and how pharmacists can help warn the public about its potential hazards.
Pharmacy Times
MAY 23, 2024
Clinical trials are using AI to handle large and complex volumes of data to develop oncology, cardiovascular, and neurologic compounds and to integrate molecular and imaging data.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
MAY 23, 2024
Combination treatment of sotorasib plus panitumumab prolongs progression-free survival in those with metastatic colorectal cancer and the KRAS G12C mutation.
Drug Topics
MAY 23, 2024
Test your knowledge of asthma and allergy triggers.
STAT
MAY 23, 2024
You’d think if there were a vaccine that would prevent tens of thousands of cases of cancer a year, people would want it for themselves and for their kids. But new data being released Thursday ahead of the annual meeting of the American Society of Clinical Oncology show that just isn’t the case.
Pharmacy Times
MAY 23, 2024
Tune into this episode of “Public Health Matters” to hear Dr. Kate Gainer’s journey in state pharmacy association and how advocacy and legislative initiatives can benefit pharmacists.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
MAY 23, 2024
Burnout is a growing crisis in health care: More than 50% of health care professionals report symptoms of it. Addressing the trauma they face at work can help. Halting burnout straddles the tension between addressing the individual factors versus the organizational factors behind it. It was once believed that burnout was related to health workers’ inability to cope with the natural stresses of their job.
Pharmacy Times
MAY 23, 2024
Fertility pharmacists understand the importance of education, awareness, and support women need to discover in navigating the complexities of fertility.
STAT
MAY 23, 2024
An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption. The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield.
Fierce Healthcare
MAY 23, 2024
Atropos Health, maker of a real-world data platform, sits at the intersection of two rapidly growing fields, real-world evidence research and artificial intelligence. | Atropos Health is getting closer to its mission of addressing the evidence gap in healthcare and secured $33 million in series B funding to help fuel its growth.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
MAY 23, 2024
I’ve been on three sides of the health care equation: I’ve beaten stage 4 colorectal cancer, I’m the mother of a son with an ultra-rare genetic abnormality, and I now work as the chief patient officer for Parexel, one of the world’s largest clinical research organizations. Having seen what people go through as they navigate the health care system and try to participate in clinical trials, I know that the road to participation must be smoother and easier — and n
PharmaVoice
MAY 23, 2024
Promises made by pharma and biotech companies show confidence in the future of their business and dedication to financial success, R&D and environmental protection.
STAT
MAY 23, 2024
Stroke prevalence has been climbing over the past decade, reversing a steady decline among all Americans while rising the most among adults under 65, a new CDC analysis reports. Strokes still strike more adults older than 65, but the increase at younger ages mirrors another recent turnaround: rates of heart failure deaths, which had been dipping, are rising the most in adults under 45.
Fierce Healthcare
MAY 23, 2024
After several years of modest or declining growth, the average pay for doctors jumped 5.9% in 2023, rebounding from a decline of 2.4% in 2022. | After several years of modest or declining growth, the average pay for doctors jumped 5.9% in 2023, rebounding from a decline of 2.4% in 2022.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
STAT
MAY 23, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Wall Street had a big reaction to H5N1 bird flu news yesterday. Was it warranted? We’ll discuss that today.
Fierce Healthcare
MAY 23, 2024
Centene's philanthropic arm is joining forces with McCormack Baron Salazar to develop new affordable housing options in multiple states. | Centene's philanthropic arm is joining forces with McCormack Baron Salazar to develop new affordable housing options in multiple states.
STAT
MAY 23, 2024
Thoughts about Cytokinetics after Wednesday night’s financing announcement : 1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too. 2.
Fierce Pharma
MAY 23, 2024
Over the last four years, with President Joe Biden milking a popular cause as an opponent of Big Pharma drug pricing, the industry has rarely seen good news coming from the White House. | Over the last four years, with President Joe Biden milking a popular cause as an opponent of Big Pharma's pricing, the industry has rarely seen good news coming from the White House.
STAT
MAY 23, 2024
An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died. The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells.
pharmaphorum
MAY 23, 2024
Merck KGaA has agreed to a $600m deal to buy Mirus Bio, a specialist in transfection reagents used in the production of cell and gene therapies.
Pharmaceutical Technology
MAY 23, 2024
AstraZeneca has entered into a worldwide licence and option agreement with Nona Biosciences for a preclinical monoclonal antibody.
pharmaphorum
MAY 23, 2024
Novo Nordisk’s second facility fire in a week is under control, although the office in Bagsvaerd affected by the latest blaze isn’t expected to be salvageable.
European Pharmaceutical Review
MAY 23, 2024
Last month, CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) was the first BCMA-targeted CAR-T cell therapy to be approved for second-line treatment of multiple myeloma by the US Food and Drug Administration (FDA). In this Q&A, Dr Imran Khan, PhD, Vice President Medical Affairs, Hematology at Johnson & Johnson Innovative Medicine, highlights the current landscape of CAR T therapies such as CARVYKTI and touches on the future direction of the sector.
pharmaphorum
MAY 23, 2024
China’s Asymchem Laboratories has agreed to take over the operation of a Pfizer manufacturing facility in Sandwich, UK, saving dozens of jobs.
STAT
MAY 23, 2024
Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference. This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.
pharmaphorum
MAY 23, 2024
Cytokinetics has been a top biotech takeover candidate for some time, thanks to blockbuster speculation about its lead drug aficamten, but a $1 billion-plus set of financing deals shows it is prepared to go to market on its own.
Fierce Healthcare
MAY 23, 2024
Interim CEO at Veradigm Shin-Yin Ho and Will Manidis, CEO and founder of ScienceIO (which was recently acquired by Veradigm), spoke about the potential of artificial intelligence on a panel at the | Veradigm and ScienceIO CEOs discussed how artificial intelligence will dramatically change the function of electronic health records, from making their contents more usable to demoting their prominence in healthcare.
pharmaphorum
MAY 23, 2024
In the post-COVID world, which start-ups will thrive and which will fizzle? Discover the fundamental strategies that separate the winners from the losers.
Fierce Pharma
MAY 23, 2024
Over the years, melanoma has become a popular testing ground for researchers to explore new immuno-oncology approaches. | With prior approvals in melanoma, Bristol Myers Squibb and Iovance are now showcasing early clinical data for their novel combinations in small first-line melanoma trials.
Expert insights. Personalized for you.
611 
Let's personalize your content